Media

Seoul Office Will Be Opening to Develop Immunomic Therapeutics Investigational Cell Therapy for Brain Cancer September 10, 2020 08:00 AM Eastern Daylight Time SEOUL--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held

Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM~25-35 % survival over 5 years from diagnosis in vaccinated GBM

REGISTER NOW Oncology Central powered by Future Science Group presents the panel discussion: Past, Present and Future of Immuno-oncology DATE: September 23, 2020 TIME: 10:00AM EDT/7:00AM PDT/15:00PM BST This panel

Poster Title: Glypican-3-LAMP: A novel DNA vaccine for liver cancer immunotherapy Presentation Date: August 17-18, 2020 3:30-5PM EST Download poster here.

ITI was chosen as one of DC Inno’s on Fire Winners for 2020 alongside Emergent Biosolutions, Novavax and Viela Bio. Check it out… https://www.americaninno.com/dc/50-on-fire/meet-dc-innos-2020-Inno-on-fire DC Inno is your source for

-Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technology and grow operations- June 24, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md. &

-First-in-Human Phase I study is anticipated to commence in 2021- June 16, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering

Data from preclinical studies demonstrates that UNITE, as a nucleic acid platform, elicits potent immune responses in mice June 11, 2020 04:05 PM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics,

Last year, the National Brain Tumor Society (NBTS) was proud to champion, help introduce and endorse the inaugural Glioblastoma (GBM) Awareness Day.  GBM Awareness Day was launched with an official,

Date and Time Thu, May 21, 2020:  7:00 PM – 9:00 PM EDT Online Event - Click here “Why does it take so long? Vaccine Development and Clinical Trials” About this

Immunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising projections by over $11M. The Korean investment group HLB Co., LTD led

Bill Hearl joins BioTalk host Rich Bendis to discuss their recent successes in funding, research, and their growth in the BioHealth Capital Region Dr. William Hearl is the founder of